Inclusion Criteria:

          -  Histologically or cytologically confirmed, newly diagnosed non-squamous NSCLC

          -  Unresectable stage IIIA or IIIB disease; patients must be surgically staged to confirm
             N2 or N3 disease; patients may have invasive mediastinal staging by mediastinoscopy,
             mediastinotomy, endobronchial ultrasound transbronchial aspiration (EBUS-TBNA),
             endoscopic ultrasound (EUS), or video-assisted thoracoscopic surgery (VATS)

          -  Patients with any tumor (T) with node (N)2 or N3 are eligible; patients with T3, N1-N3
             disease are eligible if deemed unresectable; patients with T4, any N are eligible

          -  Patients must have measurable disease, i.e., lesions that can be accurately measured
             in at least 1 dimension (longest dimension in the plane of measurement is to be
             recorded) with a minimum size of 10 mm by computed tomography (CT) scan (CT scan slice
             thickness no greater than 5 mm)

          -  Patients with a pleural effusion, which is a transudate, cytologically negative and
             non-bloody, are eligible if the radiation oncologist feels the tumor can be
             encompassed within a reasonable field of radiotherapy

          -  If a pleural effusion can be seen on the chest CT but not on chest x-ray and is too
             small to tap, the patient will be eligible; patients who develop a new pleural
             effusion after thoracotomy or other invasive thoracic procedure will be eligible

          -  The institution's pre-enrollment biomarker screening at a Clinical Laboratory
             Improvement Amendments (CLIA) certified lab documents presence of known "sensitive"
             mutations in epidermal growth factor receptor tyrosine kinase (EGFR TK) domain (exon
             19 deletion, L858) and/or EML4-anaplastic lymphoma kinase (ALK) fusion arrangement;
             either the primary tumor or the metastatic lymph node tissue may be used for testing
             of mutations

          -  The institution's pre-enrollment biomarker screening at a CLIA certified lab documents
             absence of T790M mutation in the EGFR TK domain

          -  Appropriate stage for protocol entry, including no distant metastases, based upon the
             following minimum diagnostic workup:

               -  History/physical examination, including recording of pulse, blood pressure (BP),
                  weight, and body surface area, within 45 days prior to registration

               -  Whole body fludeoxyglucose-positron emission tomography (FDG-PET)/CT (orbits to
                  mid-thighs) within 30 days prior to registration; PET/CT must be negative for
                  distant metastasis

               -  CT scan with contrast of the chest and upper abdomen to include liver and
                  adrenals (unless medically contraindicated) within 30 days prior to registration

               -  Magnetic resonance imaging (MRI) of the brain with contrast (or CT scan with
                  contrast, if MRI medically contraindicated) within 30 days prior to registration

          -  Zubrod performance status 0-1 within 14 days prior to registration

          -  Absolute neutrophil count (ANC) >= 1,000 cells/mm^3

          -  Platelets >= 100,000 cells/mm^3

          -  Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve
             hemoglobin [Hgb] >= 8.0 g/dl is acceptable)

          -  Serum creatinine < 1.5 mg/dL or calculated creatinine clearance >= 50 ml/min (by
             Cockcroft-Gault formula) within 14 days prior to registration

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit
             of normal (ULN) within 14 days prior to registration

          -  Bilirubin within normal institutional limits within 14 days prior to registration

          -  Negative serum pregnancy test within 14 days prior to registration for women of
             childbearing potential

          -  Patient must provide study specific informed consent prior to study entry, including
             consent for mandatory screening of tissue

        Exclusion Criteria:

          -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
             for a minimum of 730 days (2 years) (for example, carcinoma in situ of the breast,
             oral cavity, or cervix are all permissible)

          -  Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a
             different cancer is allowable

          -  Prior radiotherapy to the region of the study cancer that would result in overlap of
             radiation therapy fields

          -  Atelectasis of the entire lung

          -  Contralateral hilar node involvement

          -  Exudative, bloody, or cytologically malignant effusions

          -  Severe, active co-morbidity, defined as follows:

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the last 6 months

               -  Transmural myocardial infarction within the last 6 months

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time
                  of registration

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy at the time of
                  registration; hepatic insufficiency resulting in clinical jaundice and/or
                  coagulation defects

               -  Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease
                  Control and Prevention (CDC) definition; note, however, that human
                  immunodeficiency virus (HIV) testing is not required for entry into this
                  protocol; protocol-specific requirements may also exclude immuno-compromised
                  patients

          -  Pregnancy or women of childbearing potential and men who are sexually active and not
             willing/able to use medically acceptable forms of contraception

          -  Prior allergic reaction to the study drug(s) involved in this protocol